Corteria Pharmaceuticals is a spin-out company from Sanofi. The company is focused on the development of novel therapies for heart failure subpopulations: a first-in-class CRF2 peptide agonist for outpatient worsening heart failure (OWHF) and a first-in-class vasopressin neutralizing antibody for the treatment of acute heart failure with hyponatremia (AHF).
- CEO and Cofounder: Philip Janiak
- CSO and Cofounder: Marie-Laure Ozoux
- Location: París
- Website: corteriapharma.com